Reduced glycaemic variability with once-weekly semaglutide vs active comparators in post hoc analysis of the SUSTAIN programme

被引：0
|
作者：
Jodar, E. [1 ]
Aroda, V. R. [2 ]
Kose, Y. [3 ]
Kaltoft, M. [3 ]
Sondergaard, A. L. [3 ]
Pratley, R. [4 ]
机构：
[1] Univ Hosp Quiron Salud, Madrid, Spain
[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[3] Novo Nordisk AS, Soborg, Denmark
[4] AdventHlth Translat Res Inst, Orlando, FL USA
来源：
DIABETOLOGIA | 2021年 / 64卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
481
引用
收藏
页码：250 / 250
页数：1
相关论文
共 50 条
  • [1] Reduced Glycemic Variability with Once-Weekly Semaglutide vs. Active Comparators in Post-hoc Analysis of the SUSTAIN Program
    Pratley, Richard E.
    Aroda, Vanita R.
    Hindsberger, Charlotte
    Kose, Yasemin
    Kaltoft, Margit
    Jodar, Esteban
    DIABETES, 2021, 70
  • [2] Derived time in glycaemic range with once-weekly semaglutide vs active comparator: post hoc analysis from the SUSTAIN clinical trial programme
    Aroda, V. R.
    De Block, C.
    Kaltoft, M.
    Lawson, J.
    Sondergaard, A. L.
    Philis-Tsimikas, A.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 251 - 251
  • [3] Greater Proportions of Subjects Achieved Composite Endpoints with Once-Weekly Semaglutide vs. Comparators in SUSTAIN Trials
    Gaede, Peter
    Catarig, Andrei-Mircea
    Dungan, Kathleen M.
    Hindsberger, Charlotte
    Ollgaard, Jens
    Bain, Stephen C.
    DIABETES, 2021, 70
  • [4] The effect of once-weekly semaglutide on MACE, blood pressure and lipids by race and ethnicity: a SUSTAIN 6 post hoc analysis
    Bain, S. C.
    Desouza, C. V.
    Gondolf, T.
    Hansen, T.
    Holst, I.
    Rea, R. R.
    Seufert, J.
    DIABETOLOGIA, 2019, 62 : S365 - S365
  • [5] Effect of once-weekly semaglutide on insulin use in subjects with type 2 diabetes: a post hoc analysis of SUSTAIN 6
    Seufert, J.
    Desouza, C.
    Kirk, A. R.
    Lawson, J.
    Lingvay, I.
    Sondergaard, A. L.
    Bain, S. C.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 251 - 252
  • [6] Efficacy and safety of once-weekly semaglutide low dose 0.5 mg vs once-weekly dulaglutide high dose 1.5 mg in type 2 diabetes: a post hoc analysis of SUSTAIN 7
    Pratley, R. E.
    Aroda, V. R.
    Gondolf, T.
    Hansen, T.
    Lingvay, I.
    Ludemann, J.
    Skjoth, T. V.
    Viljoen, A.
    DIABETOLOGIA, 2019, 62 : S374 - S374
  • [7] Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
    Pratley, Richard E.
    Aroda, Vanita R.
    Catarig, Andrei-Mircea
    Lingvay, Ildiko
    Luedemann, Joerg
    Yildirim, Emre
    Viljoen, Adie
    BMJ OPEN, 2020, 10 (11):
  • [8] Once-weekly semaglutide vs canagliflozin in type 2 diabetes: results of the SUSTAIN 8 trial
    Lingvay, I.
    Catarig, A.
    Frias, J. P.
    Kumar, H.
    Lausvig, N. L.
    le Roux, C. W.
    Thielke, D.
    Viljoen, A.
    McCrimmon, R. J.
    DIABETOLOGIA, 2019, 62 : S27 - S28
  • [9] Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China
    Ji, Linong
    Lu, Yibing
    Shen, Zewei
    Hu, Ping
    Liu, Wenyan
    Zhang, Qiu
    Shi, Bimin
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5312 - 5324
  • [10] Efficacy and safety of once-weekly semaglutide in elderly subjects with type 2 diabetes: post hoc analysis of SUSTAIN 1-5 trials
    Warren, M.
    Chaykin, L.
    Trachtenbarg, D.
    Nayak, G.
    Wijayasinghe, N.
    Cariou, B.
    DIABETOLOGIA, 2017, 60 : S378 - S379
12345